This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Cancer				
Prostate cancer	WW domain containing E3 ubiquitin protein ligase 2 (WWP2; AIP2); PTEN (MMAC1; TEP1)	<i>In vitro</i> and mouse studies suggest that inhibiting WWP2 could help treat prostate cancer. In HeLa cells, small interfering RNA knockdown of WWP2 decreased ubiquitination and increased stability of the tumor suppressor PTEN compared with those seen using control siRNA. In mice with xenograft prostate tumors, expression of WWP2 small hairpin RNA lowered tumor growth compared with expression of control shRNA. Future studies could include testing WWP2 inhibition in animal models of other cancers.	Patent and licensing status unavailable	Maddika, S. <i>et al. Nat. Cell Biol.</i> ; published online May 1, 2011; doi:10.1038/ncb2240 Contact: Junjie Chen, The University of Texas M.D. Anderson Cancer Center, Houston, Texas e-mail: jchen8@mdanderson.org Contact: Vivek Reddy, Palicharla, Centre for DNA Fingerprinting and Diagnostics, Hyderabad, India e-mail: msreddy@cdfd.org.in
		SciBX 4(19); doi:10.1038/scibx.2011.541 Published online May 12, 2011		